What is the evidence on efficacy and safety of ashwagandha (Withania somnifera) for stress or sleep improvement in a generally healthy adult without pregnancy, thyroid disease, autoimmune disorders, or severe liver or kidney impairment?

Ashwagandha for Stress and Sleep: Evidence and Safety

Ashwagandha (Withania somnifera) root extract demonstrates consistent efficacy in reducing stress and improving sleep quality in healthy adults, with doses of 300-600 mg daily showing significant benefits and an excellent safety profile across multiple randomized controlled trials.

Evidence for Efficacy

Stress Reduction

Multiple high-quality RCTs demonstrate ashwagandha's effectiveness for stress management:

• Most recent evidence (2026): A proprietary ashwagandha root extract (300 mg twice daily) showed superior reductions in perceived stress compared to both standard ashwagandha extract and placebo over 8 weeks, with significant improvements in Hamilton Anxiety Rating Scale scores and mood profiles 1.

• Sustained-release formulation (2026): Both 150 mg and 300 mg daily doses reduced Perceived Stress Scale scores by 38.6% and 41.6% respectively over 60 days, with the 300 mg dose also significantly lowering serum cortisol levels 2.

• Cognitive benefits (2021): 300 mg daily for 90 days improved memory recall, reduced total error rates in pattern recognition, and decreased stress scores from 18.7 to 13.0 on the PSS-10 scale 3.

• Dose-response meta-analysis (2026): Pooled analysis of 22 RCTs revealed large effect sizes for stress (SMD = -5.88), anxiety (SMD = -6.87), and depression (SMD = -5.68), with both linear and non-linear dose-response relationships identified 4.

Sleep Improvement

The evidence for sleep benefits is robust:

• Systematic review and meta-analysis (2021): Analysis of 5 RCTs with 400 participants showed ashwagandha produces a small but significant overall effect on sleep (SMD -0.59). Effects were most prominent in adults with diagnosed insomnia, at doses ≥600 mg/day, and with treatment duration ≥8 weeks 5.

• Specific sleep parameters (2026): The sustained-release formulation significantly improved Pittsburgh Sleep Quality Index scores, with benefits in both 150 mg and 300 mg daily doses 2.

• Mental alertness: Ashwagandha improved morning mental alertness on rising, suggesting not just sedation but actual sleep quality enhancement 5.

Safety Profile

Short to Medium-Term Safety (8-12 weeks)

The safety data is reassuring across multiple trials:

• No serious adverse events reported in any of the major RCTs examining doses from 150-600 mg daily 2, 1, 3, 6.

• Mild adverse effects were comparable to placebo groups when they occurred 6.

• Laboratory safety: No detrimental effects on hepatic, renal, cardiac, or thyroid function markers in controlled trials 1, 7.

Important Safety Caveats

Critical contraindications per FDA labeling:

• Pregnant or nursing women should consult a physician before use 8
• Children under 18 years should not use without medical supervision 8
• Persons with known medical conditions require physician consultation 8

However, emerging evidence challenges the pregnancy contraindication: A 2026 RCT in 70 pregnant women (second trimester) found that 300 mg twice daily for 12 weeks was well-tolerated with no adverse events, and actually improved hemoglobin levels, stress, and sleep quality 7. This represents a significant divergence from standard FDA labeling cautions.

Long-Term Safety Concerns

The meta-analysis explicitly notes that data on serious adverse effects with long-term use are limited, and more safety data are needed for extended use beyond 12 weeks 5. This represents a genuine knowledge gap in the evidence base.

Practical Dosing Algorithm

For stress reduction:

• Start with 300 mg once daily (sustained-release formulation preferred)
• Can increase to 300 mg twice daily (600 mg total) if inadequate response after 4 weeks
• Expect measurable benefits by 4-8 weeks

For sleep improvement:

• Use ≥600 mg daily (300 mg twice daily) for optimal effect
• Treatment duration should be ≥8 weeks for maximum benefit
• Effects are more pronounced in those with diagnosed insomnia versus general sleep complaints

For combined stress and sleep issues:

• 300 mg twice daily (600 mg total) addresses both concerns effectively
• Monitor response at 4,8, and 12 weeks

Context Within Clinical Guidelines

Important note: The major clinical practice guidelines for insomnia management from the American College of Physicians 9 and VA/DoD 10 do not address ashwagandha specifically. These guidelines:

• Strongly recommend cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment 9
• Found insufficient evidence for other herbal supplements including valerian, chamomile, and melatonin 10
• Advised against kava due to hepatotoxicity risk 10

The absence of ashwagandha from these guidelines (published 2016-2020) likely reflects the timing of evidence emergence, as the highest-quality RCTs were published in 2021-2026. The supplement should be viewed as complementary to, not replacing, evidence-based behavioral interventions for chronic insomnia.

Clinical Bottom Line

Ashwagandha 300-600 mg daily is effective for stress reduction and sleep improvement in healthy adults, with an excellent short-term safety profile up to 12 weeks. The evidence supports its use as an adjunctive intervention, particularly for individuals with moderate stress or sleep complaints who may not have access to or prefer alternatives to CBT-I or pharmaceutical options. The lack of long-term safety data beyond 12 weeks warrants caution with extended use, and the standard contraindications for pregnancy, thyroid disease, and autoimmune conditions should be respected pending further research, despite emerging positive data in pregnancy.